Andy Weymann is a prominent figure in the field of longevity, currently serving as the CEO and Director of the Board at Gelmetix. With a strong background in biotechnology and business leadership, he drives innovative solutions aimed at enhancing healthspan and lifespan. Under his guidance, Gelmetix is focused on developing groundbreaking therapies that address age-related challenges. Andy's vision and expertise position him as a key leader in advancing longevity science in Switzerland and beyond.